Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin

Authors

  • Minh-Dat Quoc Tang School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0009-0009-9702-3770
  • Nhu-Thuy Trinh School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0000-0002-3390-495X
  • Dung Vu School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0009-0000-2185-2542
  • Thu-Ha Thi Nguyen School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0000-0003-0887-7977
  • Hung Thanh Dong School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0009-0002-6910-2788
  • Toi Van Vo School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0000-0002-9551-6522
  • Binh Long Vong School of Biomedical Engineering, International University, Ho Chi Minh 700000, Vietnam and Vietnam National University Ho Chi Minh City (VNU-HCM), Ho Chi Minh 700000, Vietnam https://orcid.org/0000-0002-2117-4312

DOI:

https://doi.org/10.5599/admet.1845

Keywords:

Chemotherapy, reactive oxygen species, ROS scavengers, micelles nanoparticles, nanomedicine
Graphical Abstract

Abstract

Background and Purpose: The utilization of doxorubicin (DOX) in clinal trials is also challenging owing to its adverse effects, including low oral bioavailability, generation of reactive oxygen species (ROS), cardiotoxicity, and epithelial barrier damage. Recently, scavenging of ROS reduced the cytotoxicity of DOX, suggesting a new approach for using DOX as an anticancer treatment. Thus, in this study, non-silica and silica redox nanoparticles (denoted as RNPN and siRNP, respectively) with ROS scavenging features have been designed to encapsulate DOX and reduce its cytotoxicity. Experimental Approach: DOX-loaded RNPN (DOX@RNPN) and DOX-loaded siRNP (DOX@siRNP) were prepared by co-dissolving DOX with RNPN and siRNP, respectively. The size and stability of nanoparticles were characterized by the dynamic light scattering system. Additionally, encapsulation efficiency, loading capacity, and release profile of DOX@RNPN and DOX@siRNP were identified by measuring the absorbance of DOX. Finally, the cytotoxicity of DOX@RNPN and DOX@siRNP against normal murine fibroblast cells (L929), human hepatocellular carcinoma cells (HepG2), and human breast cancer cells (MCF-7) were also investigated. Key results: The obtained result showed that RNPN exhibited a pH-sensitive character while silanol moieties improved the stability of siRNP in physiological conditions. DOX@RNPN and DOX@siRNP were formed at several tens of nanometers in diameter with narrow distribution. Moreover, DOX@siRNP stabilized under different pH buffers, especially gastric pH, and improved encapsulation of DOX owing to the addition of silanol groups. DOX@RNPN and DOX@siRNP maintained anticancer activity of DOX against HepG2, and MCF-7 cells, while their cytotoxicity on L929 cells was significantly reduced compared to free DOX treatment. Conclusion: DOX@RNPN and DOX@siRNP could effectively suppress the adverse effect of DOX, suggesting the potential to become promising nanomedicines for cancer treatments.

Downloads

Download data is not yet available.

References

J. Sun, Q. Wei, Y. Zhou, J. Wang, Q. Liu, H. Xu. A systematic analysis of FDA-approved anticancer drugs. BMC Systems Biology 11 (2017) 1-17. https://doi.org/10.1186/s12918-017-0464-7

L. Gianni, J.L. Zweier, A. Levy, C. Myers. Characterization of the cycle of iron-mediated electron transfer from Adriamycin to molecular oxygen. Journal of Biological Chemistry 260 (1985) 6820-6826. https://doi.org/10.1016/S0021-9258(18)88854-8

R.D. Olson, P.S. Mushlin. Doxorubicin cardiotoxicity: analysis of prevailing hypotheses. The FASEB Journal 4 (1990) 3076-3086. https://doi.org/10.1096/fasebj.4.13.2210154

H. Keizer, H. Pinedo, G. Schuurhuis, H. Joenje. Doxorubicin (adriamycin): a critical review of free radical-dependent mechanisms of cytotoxicity. Pharmacology & Therapeutics 47 (1990) 219-231. https://doi.org/10.1016/0163-7258(90)90088-J

M.S. Horenstein, R.S. Vander Heide, T.J. L'Ecuyer. Molecular basis of anthracycline-induced cardiotoxicity and its prevention. Molecular Genetics and Metabolism 71 (2000) 436-444. https://doi.org/10.1006/mgme.2000.3043

A.G. Patel, S.H. Kaufmann. How does doxorubicin work? Elife 1 (2012) e00387. https://doi.org/10.7554/eLife.00387

C.F. Thorn, C. Oshiro, S. Marsh, T. Hernandez-Boussard, H. McLeod, T.E. Klein, R.B. Altman. Doxorubicin pathways: pharmacodynamics and adverse effects. Pharmacogenetics and Genomics 21 (2011) 440. https://doi.org/10.1097/FPC.0b013e32833ffb56

R.J. Rigby, J. Carr, K. Orgel, S.L. King, P.K. Lund, C.M. Dekaney. Intestinal bacteria are necessary for doxorubicin-induced intestinal damage but not for doxorubicin-induced apoptosis. Gut Microbes 7 (2016) 414-423. https://doi.org/10.1080/19490976.2016.1215806

J.-E. Kim, H.-J. Cho, J.S. Kim, C.-K. Shim, S.-J. Chung, M.-H. Oak, I.-S. Yoon, D.-D. Kim. The limited intestinal absorption via paracellular pathway is responsible for the low oral bioavailability of doxorubicin. Xenobiotica 43 (2013) 579-591. https://doi.org/10.3109/00498254.2012.751140

S. Kotamraju, E.A. Konorev, J. Joseph, B. Kalyanaraman. Doxorubicin-induced apoptosis in endothelial cells and cardiomyocytes is ameliorated by nitrone spin traps and ebselen: role of reactive oxygen and nitrogen species. Journal of Biological Chemistry 275 (2000) 33585-33592. https://doi.org/10.1074/jbc.M003890200

M. Elsabahy, K.L. Wooley. Design of polymeric nanoparticles for biomedical delivery applications. Chemical Society Reviews 41 (2012) 2545-2561. https://doi.org/10.1039/C2CS15327K

N. Kamaly, B. Yameen, J. Wu, O.C. Farokhzad. Degradable controlled-release polymers and polymeric nanoparticles: mechanisms of controlling drug release. Chemical Reviews 116 (2016) 2602-2663. https://doi.org/10.1021/acs.chemrev.5b00346

H. Otsuka, Y. Nagasaki, K. Kataoka. PEGylated nanoparticles for biological and pharmaceutical applications. Advanced Drug Delivery Reviews 55 (2012) 403-419. https://doi.org/10.1016/j.addr.2012.09.022

T.X. Nguyen, L. Huang, M. Gauthier, G. Yang, Q. Wang. Recent advances in liposome surface modification for oral drug delivery. Nanomedicine 11 (2016) 1169-1185. https://doi.org/10.2217/nnm.16.9

J. Wang, L. Li, L. Wu, B. Sun, Y. Du, J. Sun, Y. Wang, Q. Fu, P. Zhang, Z. He. Development of novel self-assembled ES-PLGA hybrid nanoparticles for improving oral absorption of doxorubicin hydrochloride by P-gp inhibition: In vitro and in vivo evaluation. European Journal of Pharmaceutical Sciences 99 (2017) 185-192. https://doi.org/10.1016/j.ejps.2016.12.014.

J. Wang, L. Li, Y. Du, J. Sun, X. Han, C. Luo, X. Ai, Q. Zhang, Y. Wang, Q. Fu. Improved oral absorption of doxorubicin by amphiphilic copolymer of lysine-linked ditocopherol polyethylene glycol 2000 succinate: in vitro characterization and in vivo evaluation. Molecular Pharmaceutics 12 (2015) 463-473. https://doi.org/10.1021/mp500833m

L.B. Vong, T. Yoshitomi, H. Matsui, Y. Nagasaki. Development of an oral nanotherapeutics using redox nanoparticles for treatment of colitis-associated colon cancer. Biomaterials 55 (2015) 54-63. https://doi.org/10.1016/j.biomaterials.2015.03.037

T. Yoshitomi, Y. Ozaki, S. Thangavel, Y. Nagasaki. Redox nanoparticle therapeutics to cancer—increase in therapeutic effect of doxorubicin, suppressing its adverse effect. Journal of Controlled Release 172 (2013) 137-143. https://doi.org/10.1016/j.jconrel.2013.08.011

P. Chonpathompikunlert, C.-H. Fan, Y. Ozaki, T. Yoshitomi, C.-K. Yeh, Y. Nagasaki. Redox nanoparticle treatment protects against neurological deficit in focused ultrasound-induced intracerebral hemorrhage. Nanomedicine 7 (2012) 1029-1043. https://doi.org/10.2217/nnm.12.2

T. Yoshitomi, A. Hirayama, Y. Nagasaki. The ROS scavenging and renal protective effects of pH-responsive nitroxide radical-containing nanoparticles. Biomaterials 32 (2011) 8021-8028. https://doi.org/0.1016/j.biomaterials.2011.07.014

T.-H.T. Nguyen, N.-T. Trinh, H.N. Tran, H.T. Tran, P.Q. Le, D.-N. Ngo, H. Tran-Van, T. Van Vo, L.B. Vong, Y. Nagasaki. Improving silymarin oral bioavailability using silica-installed redox nanoparticle to suppress inflammatory bowel disease. Journal of Controlled Release 331 (2021) 515-524. https://doi.org/10.1016/j.jconrel.2020.10.042

T. Yoshitomi, Y. Nagasaki. Development of silica-containing redox nanoparticles for medical applications. Biomaterials Science 3 (2015) 810-815. https://doi.org/10.1039/C5BM00057B

H.T. Tran, L.B. Vong, Y. Nishikawa, Y. Nagasaki. Sorafenib-loaded silica-containing redox nanoparticles for oral anti-liver fibrosis therapy. Journal of Controlled Release 345 (2022) 880-891. https://doi.org/10.1016/j.jconrel.2022.04.002

M. Su, H. Su, B. Du, X. Li, G. Ren, S. Wang. Mesoporous silica with monodispersed pores synthesized from the controlled self-assembly of silica nanoparticles. Korean Journal of Chemical Engineering 32 (2015) 852-859. https://doi.org/10.1007/s11814-014-0270-5

D.J. McClements. Edible lipid nanoparticles: Digestion, absorption, and potential toxicity. Progress in Lipid Research 52 (2013) 409-423. https://doi.org/10.1016/j.plipres.2013.04.008

S. Abbad, C. Wang, A.Y. Waddad, H. Lv, J. Zhou. Preparation, in vitro and in vivo evaluation of polymeric nanoparticles based on hyaluronic acid-poly (butyl cyanoacrylate) and D-alpha-tocopheryl polyethylene glycol 1000 succinate for tumor-targeted delivery of morin hydrate. International Journal of Nanomedicine 10 (2015) 305. https://doi.org/10.2147/IJN.S73971

J. Li, Z. Li, T. Zhou, J. Zhang, H. Xia, H. Li, J. He, S. He, L. Wang. Positively charged micelles based on a triblock copolymer demonstrate enhanced corneal penetration. International Journal of Nanomedicine 10 (2015) 6027. https://doi.org/10.2147/IJN.S90347

Y. Wang, L. Li, J. Li, B. Yang, C. Wang, W. Fang, F. Ji, Y. Wen, F. Yao. Stable and pH-responsive polyamidoamine based unimolecular micelles capped with a zwitterionic polymer shell for anticancer drug delivery. RSC Advances 6 (2016) 17728-17739. https://doi.org/10.1039/C5RA25505H

Q. Zhang, F. Liu, K.T. Nguyen, X. Ma, X. Wang, B. Xing, Y. Zhao. Multifunctional mesoporous silica nanoparticles for cancer‐targeted and controlled drug delivery. Advanced Functional Materials 22 (2012) 5144-5156. https://doi.org/10.1002/adfm.201201316

A.C. Alves, A. Magarkar, M. Horta, J.L. Lima, A. Bunker, C. Nunes, S. Reis. Influence of doxorubicin on model cell membrane properties: insights from in vitro and in silico studies. Scientific Reports 7 (2017) 6343. https://doi.org/10.1038/s41598-017-06445-z

Y. Kato, S. Ozawa, C. Miyamoto, Y. Maehata, A. Suzuki, T. Maeda, Y. Baba. Acidic extracellular microenvironment and cancer. Cancer Cell International 13 (2013) 89. https://doi.org/10.1186/1475-2867-13-89

E.S. Lee, K. Na, Y.H. Bae. Doxorubicin loaded pH-sensitive polymeric micelles for reversal of resistant MCF-7 tumor. Journal of Controlled Release 103 (2005) 405-418. https://doi.org/10.1016/j.jconrel.2004.12.018

Q.N. Nguyen-Trinh, K.X.T. Trinh, N.-T. Trinh, N. Li, Y. Nagasaki, L.B. Vong. A silica-based antioxidant nanoparticle for oral delivery of Camptothecin which reduces intestinal side effects while improving drug efficacy for colon cancer treatment. Acta Biomaterialia 143 (2022) 459-470. https://doi.org/10.1016/j.actbio.2022.02.036

M. Li, F. Cheng, C. Xue, H. Wang, C. Chen, Q. Du, D. Ge, B. Sun. Surface modification of Stöber silica nanoparticles with controlled moiety densities determines their cytotoxicity profiles in macrophages. Langmuir 35 (2019) 14688-14695. https://doi.org/10.1021/acs.langmuir.9b02578

Downloads

Published

04-07-2023 — Updated on 04-07-2023

How to Cite

Tang, M.-D. Q., Trinh, N.-T., Vu, D., Nguyen, T.-H. T., Dong, H. T., Vo, T. V., & Vong, B. L. (2023). Preparation of self-assembly silica redox nanoparticles to improve drug encapsulation and suppress the adverse effect of doxorubicin. ADMET and DMPK, 11(4), 551–560. https://doi.org/10.5599/admet.1845

Issue

Vol. 11 No. 4 (2023)

Section

Original Scientific Articles

License

Creative Commons лиценца
Articles are published under the terms and conditions of the
Creative Commons Attribution license 4.0 International.

Funding data